CINCINNATI, Oct. 16 Kendle (Nasdaq: KNDL) todayannounced it will release its third quarter 2008 financial results after theclose of business on Tuesday, Nov. 4, 2008. The Company will host a telephoneconference call and simultaneous webcast on Wednesday, Nov. 5 at 8:30 a.m.Eastern Time. A question and answer session will follow.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )
Conference Call Instructions
To participate in the telephone conference call, interested parties in theUnited States and Canada should dial (800) 399-0069. Participants outsideNorth America should dial (706) 643-3694. A replay will be available through 5p.m. Eastern Time on Dec. 5 by dialing (706) 645-9291 and entering conferenceID number 69053655.
To access the live webcast, visit the Company Web site at www.kendle.comor link to the Webcast directly athttp://www.videonewswire.com/event.asp?id=52362 . Instructions for accessingthe webcast are provided at both sites. The webcast will be archived athttp://www.kendle.com (click on "Investors" and then "Events & Presentations")shortly after the call for on-demand replay through 5 p.m. Eastern Time onDec. 5. Please note that webcast participants will not be able to askquestions.
System requirements for the webcast include Windows Media Player softwareand at least a 28.8 Kbps connection to the Internet. Media Player isdownloadable at no charge fromhttp://www.microsoft.com/windows/windowsmedia/default.aspx .
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinicalresearch organization providing the full range of early- to late-stageclinical development services for the world's biopharmaceutical industry. Ourfocus is on innovative solutions that reduce cycle times for our customers andaccelerate the delivery of life-enhancing drugs to market for the benefit ofpatients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning 90 countries, along with industry-leading patient access and retention capabilities and broad therapeuticexpertise, to meet our customers' clinical development challenges.
Kendle was recognized by FORTUNE magazine as one of the 100 fastest-growing companies in the United States for 2008. The company also has beenrecognized as, "Top CRO to Work With" in the Thomson CenterWatch 2007 surveyof U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading globalpharmaceutical publication Scrip World Pharmaceutical News.
Additional information and investor kits are available upon request fromKendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from thecompany's Web site at http://www.kendle.com .
SOURCE Kendle International Inc.